Actemra Access: Roche Open To Partnering Patent Pools
Roche is open to considering tie-ups with the Medicines Patent Pool or other voluntary patent pools to assess partners for Actemra, as part of efforts to broaden access to the immunotherapy for COVID-19. With a patent non-assert declaration on tocilizumab already in place, activists say the geographic scope of patent licenses will need to be broadened to have any real impact.
You may also be interested in...
While some cancer centers report sufficient stocks of the drug, they have already been turning to potential alternatives due to supply issues that could last for weeks or months.
After the WHO recommended the use of IL-6 receptor blockers to treat patients hospitalized with severe or critical COVID-19, Actemra/RoActemra originator Roche pledged not to enforce IP covering the tocilizumab brand in low- and middle-income countries during the pandemic. But humanitarian organization MSF says this does not go far enough.
Actemra finally gains an emergency use authorization, Lilly's antibodies withdrawn again amid Delta variant concerns, plus Latin America’s belief in an anti-parasite drug in COVID-19 could soon be punctured.